10-Q: Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Elicio Therapeutics reports a net loss of $11.8 million for the first quarter of 2024, with ongoing development of its cancer immunotherapies.

Summary

• Elicio Therapeutics, a clinical-stage biotechnology company, reported a net loss of $11.8 million for the three months ended March 31, 2024, compared to a net loss of $8.0 million for the same period in 2023.
• The company's research and development expenses increased to $7.6 million, up from $5.5 million in the prior year, primarily due to advancing the ELI-002 clinical program.
• General and administrative expenses also rose to $2.7 million from $2.3 million, driven by increased personnel costs and professional fees.
• As of March 31, 2024, Elicio had $11.9 million in cash and cash equivalents and an accumulated deficit of $154.0 million.
• The company anticipates that its current cash reserves will fund operations into the third quarter of 2024, but additional financing will be required to continue development of its product candidates.
• Elicio is developing immunotherapies for cancer and infectious diseases, focusing on its Amphiphile (AMP) technology to target lymph nodes and generate T-cell responses.
• The company's pipeline includes ELI-002, a cancer vaccine in Phase 2 clinical trials, and preclinical programs ELI-007 and ELI-008.
• The company completed a reverse merger with Angion Biomedica Corp. on June 1, 2023, with Former Elicio being treated as the acquirer for accounting purposes.

Sentiment

Score: 4

Explanation: The document highlights significant financial losses and concerns about the company's ability to continue as a going concern, which are major negatives. However, the company is actively advancing its clinical programs and seeking regulatory approvals, which are positive signs. The overall sentiment is cautiously negative due to the financial risks.

Positives

• The company is actively advancing its lead product candidate, ELI-002, to late-stage clinical trials.
• Elicio is expanding its pipeline of product candidates and preclinical programs.
• The company is working to maintain, expand, protect and defend its intellectual property portfolio.
• Elicio is actively seeking regulatory approval for its investigational medicines.

Negatives

• The company experienced a net loss of $11.8 million for the first quarter of 2024.
• Elicio has an accumulated deficit of $154.0 million.
• The company's current cash reserves are only expected to fund operations into the third quarter of 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is experiencing negative cash flows from operating activities.

Risks

• The company's ability to obtain additional funding is uncertain.
• There is a risk that the company may have to reduce or scale back operations if additional capital is not secured.
• The company's product candidates may not be successful in clinical trials.
• The company may face delays in obtaining regulatory approvals.
• The company's intellectual property may not be adequately protected.
• The company is reliant on third parties for clinical trials and manufacturing.
• The company may not be able to obtain favorable terms for collaborations or licensing agreements.

Future Outlook

The company expects to incur substantial expenditures in the foreseeable future for the development of its product candidates and will require additional financing to continue this development. The company believes that its cash on hand will enable it to fund its operations into the third quarter of calendar year 2024 based on its current plan.

Management Comments

• The company plans to address its going concern condition through the sale of common stock in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions.
• Management is committed to continuous improvement of our internal control over financial reporting and will continue to diligently review our internal control over financial reporting.

Industry Context

Elicio is operating in the competitive biotechnology sector, focusing on cancer immunotherapies. The company's approach of targeting lymph nodes with its AMP technology aligns with the industry's focus on enhancing T-cell responses for effective cancer treatment. The company's off-the-shelf therapeutic approach contrasts with personalized vaccine approaches, which may offer advantages in terms of manufacturing timelines and costs.

Comparison to Industry Standards

• Elicio's cash burn rate and net losses are typical for a clinical-stage biotech company, but the company's cash runway is shorter than some peers.
• Comparable companies in the immuno-oncology space include companies like BioNTech, Moderna, and Gritstone Bio, which are also developing cancer vaccines and immunotherapies.
• Elicio's focus on lymph node targeting is a differentiating factor, but the success of this approach will depend on clinical trial results.
• The company's reliance on external partners for clinical trials and manufacturing is common in the industry, but it also introduces risks related to timelines and costs.
• Elicio's financial position is weaker than some of its larger competitors, which may limit its ability to fund large-scale clinical trials and commercialization efforts.

Related Party Transactions

• The Company paid $0 for the three months ended March 31, 2024 for consulting services provided by an entity affiliated with the Companys former interim chief financial officer and former board member.
• In March 2024, the Company entered into the March Subscription Agreement with the Purchaser for purposes of the March Offering. The Purchaser is an entity controlled by a director of the Company.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment if the company is unable to secure additional funding.
• Employees may be impacted by potential reductions in operations if the company's financial situation does not improve.
• Customers (potential patients) may be impacted by delays in the development and availability of the company's product candidates.
• Suppliers and creditors may face increased risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company will continue to advance its lead product candidate, ELI-002, to late-stage clinical trials.
• The company will continue to advance its preclinical programs to clinical trials.
• The company will continue to seek regulatory approval for its investigational medicines.
• The company will continue to maintain, expand, protect and defend its intellectual property portfolio.
• The company will continue to seek additional financing to fund its operations.

Key Dates

Keywords

immunotherapies, cancer, clinical trials, biotechnology, lymph nodes, T-cell response, ELI-002, AMP technology, financial results, going concern